In a significant move to strengthen its presence in key therapy areas, Pfizer India has partnered with Cipla to market and distribute four of its legacy brands in India, including the popular Corex cough syrups.
The agreement gives Cipla the sole rights to sell and distribute two Corex variants, Dx and LS, along with Dolonex (an NSAID), Neksium (a proton pump inhibitor), and Dalacin C (an oral antibiotic). Pfizer will continue to manufacture and supply the products, while Cipla will leverage its deep distribution network to meet the needs of millions of patients.
The agreement is for a five-year period, with no upfront consideration. The financial terms of the deal have not been disclosed. This partnership marks the first collaboration between the two pharma giants in India, where Pfizer has operated for over 75 years.
According to Meenakshi Nevatia, Country President at Pfizer India, “this partnership combines Pfizer’s innovation with Cipla’s deep distribution network to meet the needs of millions of patients”. Cipla COO Achin Gupta called the tie-up a step toward “making strong brands even stronger”. The alliance is expected to reinforce Cipla’s footprint across respiratory and gastrointestinal segments.
Some of the key expectations from this deal include:
Remember, this is a business development, not a prediction of future performance. It’s essential to do your own research and consider multiple sources before making any investment decisions.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram